Xanthus Pharmaceuticals, Inc. has licensed from Schering AG the exclusive right to develop and commercialize oral fludarabine in the U.S. Oral fludarabine is currently marketed by Schering AG in the EU and Canada under the name, Fludara, for the treatment of relapsed B-cell chronic lymphocytic leukemia (CLL). Intravenous (IV) fludarabine has been available for several years as a single treatment for patients with CLL whose disease has relapsed following prior therapy. The IV formulation was ap...